April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Intravenous Factor VII-Verteporfin for Targeted Photodynamic Therapy in Experimental Choroidal Neovascularization
Author Affiliations & Notes
  • R. A. Adelman
    Ophthal & Visual Science,
    Yale Univ Sch of Medicine, New Haven, Connecticut
  • F. Lu
    Ophthal & Visual Science,
    Yale Univ Sch of Medicine, New Haven, Connecticut
  • Z. Hu
    Obstetrics and Gynecology,
    Yale Univ Sch of Medicine, New Haven, Connecticut
  • J. Sinard
    Ophthal & Visual Science,
    Yale Univ Sch of Medicine, New Haven, Connecticut
  • A. Garen
    Molecular Biophysics and Biochemistry,
    Yale Univ Sch of Medicine, New Haven, Connecticut
  • Footnotes
    Commercial Relationships  R.A. Adelman, Yale Univ, P; F. Lu, None; Z. Hu, Yale Univ, P; J. Sinard, None; A. Garen, Yale Univ, P.
  • Footnotes
    Support  Leir Foundation, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3091. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R. A. Adelman, F. Lu, Z. Hu, J. Sinard, A. Garen; Intravenous Factor VII-Verteporfin for Targeted Photodynamic Therapy in Experimental Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3091.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy and safety of factor VII (fVII)-verteporfin for targeted photodynamic therapy (TPT) as compared to non-targeted photodynamic therapy (PDT) in a rat model of choroidal neovascularization (CNV). fVII-verteporfin binds tightly and specifically to tissue factor, which is expressed on endothelial cells of CNV but not normal vasculature.

Methods: : In Brown-Norway rats CNV lesions were induced by laser photocoagulation of the retina. After 3 weeks, the rats were injected intravenously with fVII-verteporfin (0.5 mg/m2 and 1.0 mg/m2) or verteporfin (6.0 mg/ m2). Randomly selected lesions were treated with 689 nm laser 30 or 60 minutes later. Lesions were evaluated by fundus photography, fluorescein angiography and histopathology.

Results: : The rats injected with verteporfin showed leakage in 75% of the CNV lesions on day 7 and 100% of lesions on day 14. The rats injected with fVII-verteporfin at a dose of 0.5 mg/m2 showed leakage in 33% and 36% of the CNV lesions on day 7 and day 14 respectively. When the dose was increased to 1.0 mg/m2, leakage was detected in 25% and 23% of the CNV lesions on day 7 and day 14 respectively. No ocular side effect was detected by histopathologic evaluation.

Conclusions: : The frequency of leakage in CNV lesions was significantly reduced using fVII-verteporfin for targeted PDT as compared to non-targeted PDT. The efficacious dose with fVII-verteporfin was about 1/10th of the dose usually used with verteporfin. Using fVII-verteporfin for targeted PDT may improve the efficacy and safety of PDT for treating choroidal neovascularization.

Keywords: age-related macular degeneration • choroid: neovascularization • photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×